Maravai LifeSciences
MRVI
159 hedge funds and large institutions have $421M invested in Maravai LifeSciences in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 56 reducing their positions, and 22 closing their positions.
4,049% more call options, than puts
Call options by funds: $3.44M | Put options by funds: $83K
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
12% more capital invested
Capital invested by funds: $375M → $421M (+$45.8M)
1% less funds holding
Funds holding: 160 → 159 (-1)
1.13% less ownership
Funds ownership: 90.36% → 89.23% (-1.1%)
18% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.48M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.95M |
| 3 |
GAI
General American Investors
New York
|
+$4.88M |
| 4 |
Millennium Management
New York
|
+$4.57M |
| 5 |
First Eagle Investment Management
New York
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1WCM
12 West Capital Management
New York
|
-$12.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.59M |
| 3 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$5.52M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.36M |
| 5 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$4.86M |
MRVI Hedge Fund Activity: Q4 2025 in Review
159 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2025, worth a combined $421M — up 12% from $375M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MRVI positions and 22 closed out — a net gain of 3 holders — while 46 added to existing stakes and 56 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $9.48M. The largest seller was 12 West Capital Management, cutting an estimated $12.1M.
- 159 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2025, down from 160 in Q3 2025.
- Funds reported $421M of Maravai LifeSciences stock for Q4 2025, up 12% quarter-over-quarter.
- 25 funds opened new Maravai LifeSciences positions in Q4 2025 and 22 closed out, a net change of +3 holders.
- The largest Maravai LifeSciences buyer in Q4 2025 was Point72 Asset Management, an estimated $9.48M added.
- The largest Maravai LifeSciences seller in Q4 2025 was 12 West Capital Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2025.